Evolocumab for Primary Prevention of Cardiovascular Disease

Key Points

• To evaluate the effectiveness of evolocumab in reducing cardiovascular disease risk in individuals with no history of heart disease.
• Randomized trial design
• Participants had no previous cardiovascular events
• Administration of evolocumab as a lipid-lowering intervention
• Evolocumab significantly reduced LDL cholesterol levels (by X%) compared to placebo, p<0.05.
• There was a notable decrease in cardiovascular events during the follow-up period.
• Indicated a promising potential for primary prevention of cardiovascular disease.